AR008673A1 - Formulaciones estables de proteinas y acidos nucleico que utilizan vehiculos no acuosos, anhidridos, aproticos, hidrofobos, no polares con bajareactividad - Google Patents

Formulaciones estables de proteinas y acidos nucleico que utilizan vehiculos no acuosos, anhidridos, aproticos, hidrofobos, no polares con bajareactividad

Info

Publication number
AR008673A1
AR008673A1 ARP970104744A ARP970104744A AR008673A1 AR 008673 A1 AR008673 A1 AR 008673A1 AR P970104744 A ARP970104744 A AR P970104744A AR P970104744 A ARP970104744 A AR P970104744A AR 008673 A1 AR008673 A1 AR 008673A1
Authority
AR
Argentina
Prior art keywords
administration
nucleic acids
stable formulations
aprotic
hydrophobic
Prior art date
Application number
ARP970104744A
Other languages
English (en)
Spanish (es)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR008673A1 publication Critical patent/AR008673A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP970104744A 1996-10-16 1997-10-15 Formulaciones estables de proteinas y acidos nucleico que utilizan vehiculos no acuosos, anhidridos, aproticos, hidrofobos, no polares con bajareactividad AR008673A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2816796P 1996-10-16 1996-10-16
US5292097P 1997-07-15 1997-07-15

Publications (1)

Publication Number Publication Date
AR008673A1 true AR008673A1 (es) 2000-02-09

Family

ID=26703379

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104744A AR008673A1 (es) 1996-10-16 1997-10-15 Formulaciones estables de proteinas y acidos nucleico que utilizan vehiculos no acuosos, anhidridos, aproticos, hidrofobos, no polares con bajareactividad

Country Status (10)

Country Link
US (3) US6264990B1 (forum.php)
EP (1) EP0939655B1 (forum.php)
JP (1) JP2002513390A (forum.php)
AR (1) AR008673A1 (forum.php)
AT (1) ATE218886T1 (forum.php)
AU (1) AU4821197A (forum.php)
CA (1) CA2264776C (forum.php)
DE (1) DE69713378T2 (forum.php)
IN (1) IN184589B (forum.php)
WO (1) WO1998016250A1 (forum.php)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN184589B (forum.php) * 1996-10-16 2000-09-09 Alza Corp
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
DE19940748A1 (de) * 1999-08-27 2001-03-01 Hugo Seinfeld Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide
WO2001037804A2 (en) * 1999-11-22 2001-05-31 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials
WO2001066137A1 (en) * 2000-03-07 2001-09-13 Merck & Co., Inc. Adenovirus formulations
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
JP2005505429A (ja) * 2001-06-28 2005-02-24 マイクロチップス・インコーポレーテッド マイクロチップリザーバデバイスを密閉シーリングするための方法
WO2003048665A1 (en) 2001-12-03 2003-06-12 Massachusetts Institute Of Technology Microscale lyophilization and drying methods for the stabilization of molecules
NZ534377A (en) * 2002-03-13 2008-04-30 Collagenex Pharm Inc Water-based topical delivery system consisting of cholesterol, fatty acids water and a phospholipid/ceramide portion.
KR100725973B1 (ko) * 2002-08-16 2007-06-11 마이크로칩스 인코포레이티드 전열적 제거를 이용한 제어 방출 장치 및 방법
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
NZ539107A (en) * 2002-09-27 2008-11-28 Powderject Res Ltd Nucleic acid coated particles
AU2003284018A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for neural stimulation and controlled drug delivery
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP3597262B1 (en) * 2002-12-20 2023-12-27 Xeris Pharmaceuticals, Inc. Formulation for intracutaneous injection
CA2521979A1 (en) * 2003-04-09 2004-10-28 University Of Utah Research Foundation Compositions and methods related to production of erythropoietin
WO2004096176A2 (en) * 2003-04-25 2004-11-11 Boston Scientific Scimed Inc. Solid drug formulation and device for storage and controlled delivery thereof
US7892205B2 (en) * 2003-06-06 2011-02-22 Boston Scientific Scimed, Inc. Device and method for delivering micronized therapeutic agents in the body
AU2004285603A1 (en) * 2003-11-03 2005-05-12 Microchips, Inc. Medical device for sensing glucose
WO2006085908A2 (en) * 2004-06-01 2006-08-17 Microchips, Inc. Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
US7537590B2 (en) * 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2006026768A1 (en) * 2004-09-01 2006-03-09 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents
AU2005285279B2 (en) * 2004-09-10 2012-03-22 Becton, Dickinson And Company Reconstituting infusion device
AU2006208131A1 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5276448B2 (ja) * 2005-12-22 2013-08-28 オークウッド ラボラトリーズ，エル．エル．シー． 昇華可能な持続放出デリバリーシステム及びその製造方法
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8945529B2 (en) * 2007-03-30 2015-02-03 Helix Biopharma Corporation Biphasic lipid-vesicle compositions
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
WO2010059253A2 (en) * 2008-11-24 2010-05-27 Massachusets Institute Of Technology Methods and compositions for localized agent delivery
EP2462246B1 (en) 2009-09-28 2017-09-06 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CN103096934A (zh) * 2010-03-09 2013-05-08 詹森生物科技公司 非水性高浓度低粘度混悬剂
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
EP2547323B1 (en) 2010-03-17 2016-01-27 Novaliq GmbH Pharmaceutical composition for treatment of increased intraocular pressure
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103442695B (zh) 2011-03-10 2016-05-04 Xeris药物公司 肠胃外注射用肽药物的稳定制剂
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
CN108283623A (zh) 2011-05-25 2018-07-17 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
CN103930096B (zh) 2011-10-31 2017-05-31 Xeris药物公司 用于治疗糖尿病的制剂
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
JP6039152B2 (ja) 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2805367T3 (es) 2013-01-11 2021-02-11 Corsair Pharma Inc Profármacos de treprostinil
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
UY35463A (es) * 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP4043036A1 (en) 2013-09-27 2022-08-17 Massachusetts Institute of Technology Carrier-free biologically-active protein nanostructures
US10772942B2 (en) * 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
EP3828160A1 (en) 2014-07-16 2021-06-02 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2016022831A1 (en) 2014-08-06 2016-02-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11034752B2 (en) 2015-08-12 2021-06-15 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017055453A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
DK3355990T3 (da) 2015-09-30 2019-09-16 Novaliq Gmbh Semifluorinerede forbindelser og disses sammensætninger
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2017218533A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
AU2017281296B2 (en) 2016-06-23 2021-03-11 Novaliq Gmbh Topical administration method
WO2018054932A1 (en) 2016-09-22 2018-03-29 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JP7072582B2 (ja) 2017-04-21 2022-05-20 ノバリック ゲーエムベーハー ヨウ素組成物
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP4378463A3 (en) 2017-06-02 2024-10-23 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
CN119909046A (zh) 2017-10-04 2025-05-02 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
WO2019217637A1 (en) * 2018-05-09 2019-11-14 Biomatrica, Inc. Stabilization of proteins in biological samples
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
KR20210125032A (ko) 2019-02-05 2021-10-15 린디 바이오사이언시스, 아이엔씨. 세포 배양 성분 및 액체 세포 배양 배지로부터 이를 단리하는 방법
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
EP4069324B1 (en) 2019-12-06 2025-05-21 Guangzhou Bioseal Biotech Co., Ltd. Flowable fibrinogen thrombin paste
US20220162587A1 (en) * 2020-11-20 2022-05-26 Team Medical Llc Rna stabilization
WO2023044455A2 (en) * 2021-09-16 2023-03-23 Team Medical Llc Rna stabilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2342073A1 (fr) * 1976-02-27 1977-09-23 Merieux Inst Nouveau vaccin antivariolique sous forme de pate et son dispositif d'application
EP0177342A3 (en) 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins
IT8922398A0 (it) * 1989-11-16 1989-11-16 Phidea Spa Composizioni farmaceutiche ad elevato assorbimento e stabilita', comprendente una calcitonina come sostanza attiva.
US5518731A (en) * 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
WO1994006452A1 (en) 1992-09-21 1994-03-31 The Upjohn Company Sustained-release protein formulations
US5480914A (en) 1994-05-06 1996-01-02 Allergan, Inc. Nonaqueous thixotropic drug delivery suspensions and methods of their use
WO1996027393A1 (en) 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
IN184589B (forum.php) * 1996-10-16 2000-09-09 Alza Corp

Also Published As

Publication number Publication date
EP0939655B1 (en) 2002-06-12
ATE218886T1 (de) 2002-06-15
US20010038859A1 (en) 2001-11-08
DE69713378D1 (de) 2002-07-18
EP0939655A1 (en) 1999-09-08
US20040151779A1 (en) 2004-08-05
WO1998016250A1 (en) 1998-04-23
US6264990B1 (en) 2001-07-24
IN184589B (forum.php) 2000-09-09
CA2264776A1 (en) 1998-04-23
AU4821197A (en) 1998-05-11
DE69713378T2 (de) 2003-01-30
US6730328B2 (en) 2004-05-04
CA2264776C (en) 2008-11-25
JP2002513390A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
AR008673A1 (es) Formulaciones estables de proteinas y acidos nucleico que utilizan vehiculos no acuosos, anhidridos, aproticos, hidrofobos, no polares con bajareactividad
AR007714A1 (es) Una formulación no acuosa estable de un compuesto peptídico, y un método para preparar la formulación.
DE3881443D1 (de) Imidazol-verbindung und diese enthaltende biozide zusammensetzungen.
GR1000095B (el) Χορηγητες βυσματος και συνθεσεις για την κατασκευη των.
DK618388D0 (da) Stabiliserede isothiazolonpraeparater
DK204683D0 (da) Fremgangsmade til fremstilling af stabile pharmaceutiske midler indeholdende oxicamderivater
DK222688A (da) Vaesker til konditionering af tand- og knoglestoffer, deres fremstilling og anvendelse
FI882912A0 (fi) Laekemedelspreparat med finfoerdelade ebselen-kristaller.
IT8319857A0 (it) Agenti antiflogistici/antipiretici/analgesici contenenti derivati di teobromina o teofillina come ingrediente attivo.
DE69720269D1 (de) Gelierungsstabiele polyhalogenphosphazenverbindungen
IT1208445B (it) Procedimento per la conservazione di tessuto organico vivo mediante congelamento
DK378988D0 (da) Dopamin-beta-hydroxylaseinhibitorer, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende disse forbindelser
JPS55147217A (en) Stable injection containing indoleacetic acid or indanacetic acid derivative
IT1120983B (it) Composizione stabilizzata contenente proteine del latte particolarmente per alimentazione di animali e procedimento per la sua preparazione
DK43080A (da) Cyclisk hexapeptid og foderstof indeholdende cyclisk hexapeptid
DE3370476D1 (en) Tetramethacrylic or tetraacrylic acid compounds and their use
IT1115238B (it) Medicina contenente n-d-xiloside di acido para-amminobenzoico come ingrediente attivo
ITMI911059A0 (it) Acido metiltauroursodesossicolico e suoi derivati terapeuticamente attivi procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono
DK712388D0 (da) Heterocyclisk substituerede oxo- eller thiophthalazinyl-eddikesyre-forbindelser og farmaceutiske praeparater indeholdende disse
EG19690A (en) Solid oral forms of application containing ifosamide as active substance
DK268783A (da) Insecticide sammensaetninger med hoej koncentration af aktivt stof
MY8600045A (en) Pharmaceutical compositions containing immunestimulating n-substituted aziridine-2-carboxylic acid derivatives
DK116687D0 (da) Farmaceutisk praeparat indeholdende aenovantroneae
IE821095L (en) Parasiticidal compositions
SE8001235L (sv) 2,2-dimetyl-1,2-dihydrokinolinderivat anvendbara som antioxidanter, jemte sett for deras framstellning och blandningar innehallande dem

Legal Events

Date Code Title Description
FB Suspension of granting procedure